Member Info for scotlouie

But ive been atound the block too many times to realise it is not a good idea to buy on a 150% rise. (For me anyone) im not saying it cant or wont go further just think ill wait it out and see how things pan out from here

If you catch the speeding ticket dip. Ill keep an eye on it. Missed it this morning, good luck all

Drums you said you had high hopes for the company and andrew. Can i ask what has changed? Other than the SP the the company is still in the same position it has been. If not strengthed with recent news. AGL is a long term play. I have seen many highs and lows within SP in my time invested in AGL yet it does not faze me one bit. I am happy to wait it out for the long term while my other shoet term trading shares in AIM can feed me the excitment of the aim market.

Well it did get down to my 0.55p level but totally missed it!

ill be in for the long term with this one so hoping they make the 100 mill MCAP :) under radar at the moment so gives us all an opportunity to load up on cheap shares before a decent RNS comes out regarding new Zealand or JV in china etc or sales contract.... all will put this one peoples watchlist so for time being ill quietly buy when I can and watch it grow in a year or two ;)

Didnt expect those. Thought it was going to be a lot better. Oh well

My money's still on tues :)

Thinking along the same way. Who would u do a presentation on poor results. Doesnt make sense. Saying that. Volume has been low here which if they were that good why isnt the big guys jumping in. It is AIM after all. No mater how tight a ship companies run. The big boys always get first dibs at low sp! Be interesting anyway. Guessing results will be tues morning. Hope momentum builds onto weekend

"There are a number of more significant growth opportunities which may crystallise in 2016;   -      The building of a new facility in New Zealand to accommodate a specific customer requirement; -      The establishment of a joint-venture in China in order to work in the Chinese market with the right partner so that our products can service particular market segments cost effectively; and -      The commercialisation of the IP from ChondroMimetic, a treasure trove of value enhancing opportunities. This however will require its own dedicated management team if we are to retain our focus in our core business.   We continue to build our Company and its infrastructure in a relatively low risk manner by adopting a portfolio approach in a multi-product/customer/sector business model which monetises the embedded value in the business whilst enabling us to move up the value chain." A TREASURE TROVE OF VALUE Indeed it will be

Yup showing strength and encouraging to see BOD buy along with bullish results and good growth prospects i do believe they could get to their target of 100m by 2020. And going off today mcap thats a 6+ bagger if your willing to hold. I will be continuing to add :)

Youve bought back in then cash lol

I do like the wording in the results RNS. Some very subtle wording from BOD

for results :) had to pay for it but hopefully good news to follow with results :)

the girls moving

Must be due soon ?

Ive kept SVCA on the watchlist for 2years and everytime i look to get in it shoots up or positive results come out pushing price up further. Solid company. Well run and good fundamentals with excellent growth. I was just trying to be sneaky and catch a retrace. Just seems that ive missed out on a big sustainable rise. I may just buy in as view it for long term anyways. Ill keep watching in mean time

Some run SVCA is having shan!

also worth noting that since parsortix has beat cellsearch in tests and comparisons and research then there should be no reason why parsortix wont get FDA approval. when this does happen then parsortix should quickly become the leader in this field against its main competitor cellsearch. this being said the companies who use cellsearch will soon follow over to AGL's parsortix as it has proven better results. more and more companies will follow and cellsearch will need to redesign or will eventually loose out the market percentage, while AGL gains more and more percentage of this market and will dominate it the smart money knows this and will continue to build up a stake in the company.

jonesey this is referring to cellsearch that is the only system for identifying ctc which has FDA approval. still waiting on AGL's FDA approval

Bottom line could be hinting what is round the corner for MDZ We are encouraged that we are increasingly asked to pitch on longer term projects with the potential to generate substantial revenues over many months, and are continuing to build our pipeline along with a strong client base.